Monograph
C09AA09 - Fosinopril |
Propably not porphyrinogenic |
PNP |
Rationale
No evidence of significant CYP-dependent metabolism. Two references stating (probable) non- porphyrinogenicity.
Risk for gastrointestinal adverse events in the form of nausea, vomiting, diarrhoea, abdominal pain and dyspepsia motivates vigilance against insufficient intake of food, especially of carbohydrate.
Chemical description
Hydrolyzed by esterases in the liver to fosinoprilate, an ACE-inhibitor. Of this is 75% excreted in unchanged form by the kidneys, 20-30% as glucuriode conjugate and 1-5% as p-hydroxy metabolite. South African list:use with care. French list: authorized.
Therapeutic characteristics
Common side effects that can be potentially porphyrinogenic through reduction in carbohydrate intake and that also can be confused with an acute porphyria attack are nausea, vomiting, diarrhoea, abdominal pain and dyspepsia. Other common side effects are musculoskeletal pain, myalgia, fatigue, chest pain and asthenia.
IPNet drug reports
Uneventful use reported in 1 patient with acute porphyria.
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Luxembourg
Latvia
Serbia© NAPOS 2024